CTI BioPharma Corp (NASDAQ:CTIC) insider Value Fund L. P. Biotechnology acquired 6,333,333 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The shares were acquired at an average cost of $3.00 per share, for a total transaction of $18,999,999.00. The acquisition was disclosed in a filing with the SEC, which is available through this link.
CTI BioPharma Corp (CTIC) traded up $0.11 on Monday, reaching $3.32. The company’s stock had a trading volume of 633,711 shares, compared to its average volume of 424,768. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.17 and a current ratio of 2.19. The stock has a market capitalization of $142.65, a P/E ratio of -3.22 and a beta of 0.50. CTI BioPharma Corp has a one year low of $2.45 and a one year high of $4.90.
Separately, Zacks Investment Research raised CTI BioPharma from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Wednesday, December 27th.
About CTI BioPharma
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.